2010
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial
Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 160-166. PMID: 20130473, DOI: 10.1097/qai.0b013e3181cbd235.Peer-Reviewed Original ResearchConceptsTreatment-naive populationTreatment-experienced patientsCD mutationsTreatment-experienced populationsHIV viral loadConnection domainConnection domain mutationsOPTIMA trialVirologic outcomesVirologic responseARV regimenARV therapyViral loadAntiretroviral drugsAntiretroviral trialsUnivariate analysisDiminished responseFrequency of mutationsMultivariate analysisPatientsReduced susceptibilityA371VDomain mutationsResistance phenotypeTrials
2007
Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy
Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.Peer-Reviewed Original ResearchConceptsLong-term clinical trialsGenotypic resistance algorithmsClinical trialsDisease progressionHIV disease progression ratesHIV-1 pol sequencesHIV disease progressionDisease progression rateResistance algorithmsVirologic responseDrug comparisonsProgression rateVirtual phenotypeGenotypic algorithmsPol sequencesPatientsDrug resistanceResistance interpretationTrialsProgressionDrugsExpected ratesViral sequencesFirst eventSimilar time